T-DM1 as part of our standard of care with residual HER 2+ disease

T-DM1 as part of our standard of care with residual HER 2+ disease

Dr Tolaney on Standard Frontline Treatment Approaches in HER2+ Breast CancerПодробнее

Dr Tolaney on Standard Frontline Treatment Approaches in HER2+ Breast Cancer

Smilow Shares: Breast Cancer Education Series (CME) - Treatment Advances/Clinical TrialsПодробнее

Smilow Shares: Breast Cancer Education Series (CME) - Treatment Advances/Clinical Trials

Dr Waks on Ongoing Research in Residual HER2+ Breast CancerПодробнее

Dr Waks on Ongoing Research in Residual HER2+ Breast Cancer

Optimizing Therapy in HER2+ Disease with Dr. Reshma MahtaniПодробнее

Optimizing Therapy in HER2+ Disease with Dr. Reshma Mahtani

Breast Cancer Management in North Carolina: Updates for 2021 - Y. Abdou - 20210623Подробнее

Breast Cancer Management in North Carolina: Updates for 2021 - Y. Abdou - 20210623

2020 Evolution | Breast Cancer Case PresentationПодробнее

2020 Evolution | Breast Cancer Case Presentation